医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Lydia AI Raises $8 Million in Series A+ Funding Round to Insure the Next Billion People

2021年10月19日 PM10:00
このエントリーをはてなブックマークに追加


 

TORONTO

Lydia AI, formerly known as Knowtions Research, has announced the closing of $8 million USD in a Series A+ funding round. Led by existing investor, Information Venture Partners, and with participation from new investors, including 500 Global, this round brings Lydia AI’s total funding to $14 million USD.

Lydia AI is a deep learning risk scoring engine trained on global health data to generate precise health benchmarks. Insurers use Lydia AI to personalize experience, accelerate underwriting practices and develop new products. The company has partnered with a leading insurer to launch the first series of digital Lydia AI health score products.

“We believe that new sources of alternative data and AI will create digital insurance products that are easier to buy and can protect more people, especially those underserved by the industry today,” said Anthony Lee, CEO of Lydia AI. “In Asia alone, non-treatment due to lack of affordability amounted to $92 billion USD. With more data and improved predictive accuracy, we can help insurers make better risk decisions that transform customer experience for the next billion people.”

Lydia AI will be using the funding to establish itself as the new industry standard for health risk scoring, using digital medical data, by expanding the health score’s applicability to different types of health and life insurance products. The company selected Taiwan, Asia’s 4th largest insurance market, as its pilot market and plans to use its funding to expand into Japan, South Korea and South East Asia.

David Unsworth, the lead investor of the round and General Partner at Information Venture Partners, commented, “with Covid-19 shutting down face-to-face channels, we saw Lydia AI being poised to help insurers transform customer experience for the remote world. We believe Lydia AI is able to become the backbone of new digital health insurance products.”

Tony Wang, Managing Director at 500 Global, commented, “we believe in companies that solve challenging global problems, and that’s why we invested in Lydia AI. The next frontier of customers are digital-first citizens, and they have radically different needs than those who are insured today. We believe Lydia AI has the team and the technology to solve this problem.”

Lydia AI currently employs 42 people and plans to add 25 new hires to strengthen and grow a strong global presence in the next year.

To learn more about Lydia AI and how the company is making health insurance accessible and inclusive, click here.

About Lydia AI

Lydia AI is a health AI insurtech startup on a mission to insure the next billion people by making insurance personalized, easier to buy and more inclusive. Insurers work with Lydia AI to leverage new sources of data to make risk predictions which are used to personalize individual experiences, accelerate underwriting practices and develop new inclusive digital products with innovative Pay How You Live Benefits. The company has launched the first series of digital Lydia AI health score insurance products in Taiwan and plans to expand across Asia. Established in 2015, Lydia AI, formerly known as Knowtions Research, is backed by Alibaba Entrepreneurs Fund, Information Venture Partners and 500 Global with offices in Toronto and Taiwan. For more information, visit www.lydia.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005380/en/

CONTACT

Media: Vanita Thind, vanita.thind@lydia.ai

Related Posts Plugin for WordPress, Blogger...
TimeLine: ,

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease